PPP3R1 Promoter Polymorphism (Allelic Variation) Affects Tacrolimus Treatment Efficacy by Modulating E2F6 Binding Affinity
This study proposed that E2F6 suppresses the expression of PPP3R1, while rs4519508 C > T impairs the binding of E2F6, and thus elevates the level of PPP3R1, so that the inhibition of the downstream immune cytokines by TAC is attenuated. Our findings reported the potential regulatory role of a novel polymorphism, <i>PPP3R1</i> rs4519508 C > T, which may serve as pharmacodynamic-associated pharmacogenetic biomarker indicating individual response variability of tacrolimus, and thus aid the clinical management of transplant immunology.
Authors
- Shengying Qin (ORCID: https://orcid.org/0000-0002-8458-5960)
- Qinxia Xu
- Mingkang Zhong (ORCID: https://orcid.org/0000-0002-1797-0404)
- Xiaoyan Qiu (ORCID: https://orcid.org/0000-0002-6806-6749)
- Xinyi Zheng (ORCID: https://orcid.org/0000-0002-1869-4077)
- Cong Huai (ORCID: https://orcid.org/0000-0002-5946-3179)
Institutions
- Sun Yat-sen University (CN)
- Shanghai Jiao Tong University (CN)
- Fudan University (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Huashan Hospital (CN)
Publication Details
- Journal
- Biomedicines
- Published
- 2024-12-19
- DOI
- https://doi.org/10.3390/biomedicines12122896
- Primary Topic
- Signaling Pathways in Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Chinese Pharmaceutical Association
- Huashan Hospital